PACB Overview

Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops, and manufactures sequencing solutions. Its products and technology include HiFi long-read sequencing technology, which addresses a set of applications including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and other applications. Its sequencing technology supports oncology research by enabling analysis of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing researchers with insight into cancer biology. It focuses on creating sequencing systems to provide customers with a view of genomes, transcriptomes, and epigenomes. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.

Wall Street analysts forecast PACB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACB is2.40 USD with a low forecast of 2.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Pacific Biosciences of California Inc revenue for the last quarter amounts to 31.53M USD, decreased -15.12

Pacific Biosciences of California Inc. EPS for the last quarter amounts to -0.03 USD, decreased -97.92

Pacific Biosciences of California Inc (PACB) has 485 emplpoyees as of May 11 2026.

Today PACB has the market capitalization of 512.30M USD.